KATHRYN PARKER: Open Payments
NPI 1285087429 · DARDANELLE, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$518 in 27 payments from 13 companies in 2025. Trend: 2023 $329 · 2024 $71 · 2025 $518
Food & beverage: $449Education: $69
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $161 |
| Astellas Pharma US Inc | 1 | $69 |
| AstraZeneca Pharmaceuticals LP | 3 | $43 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $43 |
| Novo Nordisk Inc | 2 | $36 |
| Verona Pharma, Inc. | 1 | $26 |
| GlaxoSmithKline, LLC. | 1 | $25 |
| SHIELD THERAPEUTICS INC | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
Products named: VRAYLAR, CAPLYTA, Rybelsus, QULIPTA, FARXIGA, Ohtuvayre, TRELEGY ELLIPTA, ACCRUFER.
Industry payments across AR — which companies pay providers there.
